Key statistics
As of last trade Immunocore Holdings PLC (IMCR:NSQ) traded at 30.54, 2.76% above its 52-week low of 29.72, set on Oct 03, 2024.
52-week range
Open | 30.59 |
---|---|
High | 31.54 |
Low | 30.39 |
Bid | 30.49 |
Offer | 30.63 |
Previous close | 30.75 |
Average volume | 255.07k |
---|---|
Shares outstanding | 50.02m |
Free float | 44.70m |
P/E (TTM) | -- |
Market cap | 1.54bn USD |
EPS (TTM) | -1.07 USD |
Data delayed at least 15 minutes, as of Oct 08 2024 20:10 BST.
More ▼
- Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer
- Immunocore to present at the 2024 Cantor Global Healthcare Conference
- Immunocore announces transition of Chief Financial Officer
- Immunocore reports second quarter financial results and provides a business update
- Immunocore to report second quarter 2024 financial results and host call on August 8, 2024
- EQS-News: Substantial pipeline progress at several portfolio companies offsets rate-related market volatility
- Immunocore announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of first-line advanced or metastatic cutaneous melanoma
- Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response
- Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024
- Immunocore to present at the Jefferies Global Healthcare Conference
More ▼